CONTEXT: Systemic mastocytosis is defined as a clonal disorder of mast cells and their precursor cells and is currently classified as a myeloproliferative neoplasm. Its clinical course has a wide spectrum, ranging from indolent disease, with normal life expectancy, to highly aggressive disease, associated with multisystemic involvement and poor overall survival. The aim of this study was to report a case of indolent systemic mastocytosis, focusing on the diagnostic challenges, with a review of the literature. CASE REPORT: A 79-year-old Caucasian woman with osteoporosis was evaluated at the Emergency Department because of complaints of low back pain. Before this, she had consulted an orthopedist and had undergone some imaging examinations, namely a bone scan that revealed a "superscan" pattern. Due to her pain complaints and these test results, the patient was admitted to the Department of Internal Medicine. After undergoing several analytical tests and some additional imaging examinations to rule out some important differential diagnoses, she then underwent bone marrow biopsy, which made it possible to identify indolent systemic mastocytosis. CONCLUSION: Systemic mastocytosis is a rare entity that is difficult to diagnose. Its symptoms are often unspecific and frequently ignored. Skeletal changes may be the first and only manifestation of the disease and in some cases, like this one, the diagnosis is made only after histological examination. The key point for the diagnosis is to contemplate the possibility of systemic mastocytosis.
INTRODUCTION
Mastocytosis is a stem cell-derived clonal myeloproliferative disease with manifest mast cell (MC) accumulation in one or multiple tissues. [1] [2] [3] Since 2008, the World Health Organization (WHO) has included this disease in the category of myeloproliferative neoplasms (MPNs). 1 Mastocytosis is subdivided into two groups of disorders:
cutaneous mastocytosis (CM) and systemic mastocytosis (SM).
The former describes forms of mastocytosis that are limited to the skin, and the latter defines forms in which mast cells infiltrate extracutaneous organs, with or without skin involvement. 2, 3 In all its forms, it is a rare disorder with unknown incidence that can occur at any age, with slight preponderance among males. 4, 5 Skeletal lesions often occur in patients with systemic mastocytosis, affecting primarily the axial skeleton, pelvis and proximal ends of long bones. Although bone pain is a relatively frequent symptom, pathological fractures are rare. Osteolysis and osteosclerosis are the most common pattern of bone involvement.
These lesions can be mistaken for metastatic disease, Paget's disease and hyperparathyroidism, among others. 6 Patients with systemic mastocytosis may go undiagnosed for many years until the disease manifests itself in the form of skeletal lesions, due to the nonspecific nature of its symptoms. 6 The following case report is an example of systemic mastocytosis presenting as a skeletal disorder that was diagnosed in Hospital São João, Porto, Portugal. The report focuses on the diagnostic difficulties and presents a literature review.
CASE REPORT
A 79-year-old Caucasian female living in Covilhã (an area in the countryside) was admitted to the Emergency Department (ED) of Hospital São João in July 2011, complaining of severe low back pain.
Her significant past medical history included osteoporosis, which had been diagnosed more than 10 years earlier, without any prior reports of spontaneous fractures. She had therefore been medicated with alendronate plus cholecalciferol. She also said that she did not have any known allergies, had not been in contact with animals of the countryside and had not been drinking unpasteurized milk. The patient did not have any particular history of trauma and described the onset of the pain as gradual, with four years of evolution. During these years, she was admitted to the ED several times due to pain complaints and was then discharged, medicated with analgesic drugs, thereafter remaining asymptomatic for long periods of time. She said that she did not have any constitutional symptoms like significant weight loss, fever, fatigue, malaise, night sweating or decreased appetite.
In May 2011, due to worsening of the low back pain, which was refractory to analgesia, she consulted an orthopedist who requested a spinal radiograph and a bone scan. The spinal radiograph showed some degree of osteopenia without any evidence of vertebral fractures. On the other hand, the bone scintigraphy revealed a "superscan" pattern ( Figure 1A) , which is defined as an increase in the ratio of skeletal to renal uptake in an isotopic bone scan, with decreased or absent activity of the kidneys, despite all other evidence indicating normal renal function.
Two months later, in July 2011, as a result of severe pain complaints, the patient was once more admitted to the ED. Her physical examination was unremarkable. There were no skin abnormalities, lymphadenopathy or hepatosplenomegaly. It was Figure 2 ). This biopsy was diagnostic for systemic mastocytosis. Nonetheless, the serum tryptase level was normal (tryptase: 9.10 ng/ml; normal range: < 20 ng/ml).
The patient was discharged one month after admission, with a prescription for iron supplements and analgesics. She was also referred to a hematologist for regular evaluation and follow-up. receptor. 8 These mutations are rarely found in germline cells; in fact, they are somatic in most cases. 9, 10 Familial occurrence has been reported, albeit rarely, and it remains unclear whether all of these patients had c-kit mutations. 4 Systemic mastocytosis encompasses a group of heterogeneous myeloproliferative neoplasms (MPNs) characterized by Tc bone scintigraphy, showing diffusely increased skeletal uptake of the radiotracer, with minimal activity in the soft tissues and kidneys ("superscan" pattern); B) and C) Computed tomography scan at the lumbosacral level, revealing multiple discrete osteolytic and osteoblastic lesions and diffuse osteopenia, relating to the vertebrae, sacrum and iliac bone. Patients with systemic mastocytosis may have symptoms relating to involvement of the hematopoietic system, gastrointestinal system, skin and immune system, as well as in association with coexisting hematological diseases. Laboratory examination may reveal a serum tryptase level of 20 ng/ml or higher, which would be suggestive of systemic mastocytosis, although normal levels do not rule this out. 4, 12 One additional evaluation that may be conducted because of the presentation is bone scintigraphy. In the particular case of our report, the patient presented a bone scan with a "superscan" pattern. This condition has low specificity and has been reported in cases of diffuse metabolic diseases (hyperparathyroidism, osteomalacia, Paget's disease, renal osteodystrophy and hypervitaminosis D), hematological diseases (multiple myeloma, lymphoma, systemic mastocytosis, aplastic anemia, myelofibrosis, leukemia and Waldenström macroglobulinemia), fibrous dysplasia and metastatic carcinoma, particularly from the prostate or breasts, and less commonly from the bladder or lungs. 13 Although the diagnosis of systemic mastocytosis is generally suspected on the basis of the clinical history and physical findings, and supported by laboratory procedures, it can only be established through a histological diagnosis. 4 Bone marrow examination also assists in diagnosing systemic mastocytosis associated with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). This is important, because the long-term We conducted a systematic search in the main electronic databases (PubMed, Embase, Scopus, Scirus, Lilacs, Cochrane
Library and SciELO), to find papers that reported the difficulties and challenges of the clinical approach towards ISM. In order to make the search as wide as possible, no limits were applied regarding the date of publication, the language used or the type of article (Table 1) .
With regard to treatment, patients presenting systemic mastocytosis with mediator-related symptoms should be prescribed mediator-targeting drugs (such as antihistamines, cromolyn sodium, anti-leukotriene agents, proton pump inhibitors or bisphosphonates), and these should avoid triggering stimuli that might cause mediator release from MCs. 
